IL-23 inhibitors

Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
psoriasis
by NEXT STEPS IN DERM TEAM on
Psoriasis, a chronic inflammatory skin condition, affects about 2% of children. A small subset have isolated nail involvement refractory to topical treatment that can be disabling. The development of targeted biologic agents offers safe, effective options for children with moderate-to-severe skin and nail disease. A few are now Food and Drug Administration (FDA)-approved for children. INTRODUCTIO …

Continue reading "Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment"

Translating Psoriasis Guidelines into Practice
psoriasis guidelines
by Mojgan Hosseinipour, DO, FAAD on
Before we dive into our discussion, let’s outline the Guideline-Based Approach to Treatment Selection. The International Psoriasis Council has divided psoriasis treatment classification into 2 groups: Patients who are a candidate for topical therapy, or Patients who are a candidate for systemic therapy Candidates for systemic therapy must meet at least 1 of the following …

Continue reading "Translating Psoriasis Guidelines into Practice"

Patient Buzz: Psoriasis Patients & Eye Health
psoriasis patients
by Allison Sit on
Everyday Health recently wrote an article about eye health in people with psoriasis. According to the article, about 10 percent of psoriasis patients develop problems with their eyes, including uveitis, blepharitis, conjunctivitis and iritis. For tips on how to best care for and advise psoriasis patients, I reached out to George Han, MD, PhD, director of clinical dermatology and teledermat …

Continue reading "Patient Buzz: Psoriasis Patients & Eye Health"

Successful Use of Tildrakizumab for Treatment of Palmoplantar Pustulosis
Palmoplantar Pustulosis
by NEXT STEPS IN DERM TEAM on
Palmoplantar pustulosis (PPP) is a rare, recurrent skin disorder that presents a major challenge to clinical therapy. JDD author Danilo C. Del Campo, MD, FAAD reports a case of a 69-year-old woman with a 20-year history of psoriasis with skin manifestations and clinical and pathologic features consistent with PPP. After intolerance to apremilast and unsuccessful use of topical corticosteroids and …

Continue reading "Successful Use of Tildrakizumab for Treatment of Palmoplantar Pustulosis"

IL-23 Inhibitors for Psoriasis Therapeutic Cheat Sheet
IL-23 Inhibitors
by Blair Allais, MD on
Psoriasis involves a complex inflammatory cascade mediated by various cytokine effectors. Over the past fifteen years, treatment options have evolved to include biologic medications that provide targeted inhibition of various pathways. IL-23 has emerged as an important inflammatory cytokine in the pathogenesis of psoriasis. We continue our series, Therapeutic Cheat Sheet, with a closer look at IL- …

Continue reading "IL-23 Inhibitors for Psoriasis Therapeutic Cheat Sheet"